A pharmacodynamic analysis for the co-administration of inducers of CYP3A with ticagrelor: A cautionary tale in managing patients with acute coronary syndromes

Int J Cardiol. 2016 Jul 1:214:423-5. doi: 10.1016/j.ijcard.2016.03.153. Epub 2016 Mar 24.

Authors

Ali Pourdjabbar¹, Benjamin Hibbert¹, Aun-Yeong Chong¹, Joseph Abunassar¹, Nikita Malhotra¹, Teri-Anne Whitten¹, Michel R Le May¹, Derek Y F So²; CAPITAL investigators

Affiliations

¹ Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
² Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Electronic address: dso@ottawaheart.ca.

PMID: 27088404
DOI: 10.1016/j.ijcard.2016.03.153

No abstract available

MeSH terms

Acute Coronary Syndrome / drug therapy*
Adenosine / administration & dosage
Adenosine / analogs & derivatives*
Adenosine / pharmacokinetics
Aged
Aged, 80 and over
Anticonvulsants / administration & dosage*
Cytochrome P-450 CYP3A / biosynthesis*
Cytochrome P-450 CYP3A / metabolism
Cytochrome P-450 CYP3A Inducers / administration & dosage*
Drug Administration Schedule
Drug Interactions
Epilepsy / drug therapy*
Female
Humans
Male
Middle Aged
Registries
Ticagrelor
Treatment Outcome

Substances

Anticonvulsants
Cytochrome P-450 CYP3A Inducers
CYP3A protein, human
Cytochrome P-450 CYP3A
Ticagrelor
Adenosine